The tumor necrosis factor (TNF)-α and interleukin (IL)-17 remained the most common drug targets (17/60, 28.3% for TNF-α and 18/60, 30.0% for IL-17) in the past 5 years, and all trials on TNF-α and IL-17 were for psoriasis. This evidence concerns the gene IL17A and psoriasis.